Literature DB >> 19300868

Use of biomarkers in Alzheimer's trials.

B Vellas.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19300868     DOI: 10.1007/s12603-009-0031-z

Source DB:  PubMed          Journal:  J Nutr Health Aging        ISSN: 1279-7707            Impact factor:   4.075


× No keyword cloud information.
  17 in total

1.  Knowing the natural course of biomarkers in AD: longitudinal MRI, CSF and PET data.

Authors:  W M Van Der Flier; P Scheltens
Journal:  J Nutr Health Aging       Date:  2009-04       Impact factor: 4.075

2.  Neuro-imaging: structural and functional imaging.

Authors:  G B Frisoni
Journal:  J Nutr Health Aging       Date:  2009-04       Impact factor: 4.075

3.  How can we recognize "disease modification" effects?

Authors:  E R Siemers
Journal:  J Nutr Health Aging       Date:  2009-04       Impact factor: 4.075

4.  Interpreting biomarker data in therapeutic trials.

Authors:  P S Aisen
Journal:  J Nutr Health Aging       Date:  2009-04       Impact factor: 4.075

5.  Biomarkers for Alzheimer's disease trials--biomarkers for what? A discussion paper.

Authors:  S Lovestone; M Thambisetty
Journal:  J Nutr Health Aging       Date:  2009-04       Impact factor: 4.075

6.  Challenges in the conduct of disease-modifying trials in AD: practical experience from a phase 2 trial of Tau-aggregation inhibitor therapy.

Authors:  C Wischik; R Staff
Journal:  J Nutr Health Aging       Date:  2009-04       Impact factor: 4.075

7.  Molecular imaging markers in clinical trials in Alzheimer s disease.

Authors:  A Nordberg
Journal:  J Nutr Health Aging       Date:  2009-04       Impact factor: 4.075

Review 8.  Use of biomarkers to select the target population for clinical trials in subjects with mild cognitive impairment.

Authors:  P J Visser
Journal:  J Nutr Health Aging       Date:  2009-04       Impact factor: 4.075

9.  What we have learned from the Xaliproden Sanofi-aventis trials.

Authors:  P Douillet; J M Orgogozo
Journal:  J Nutr Health Aging       Date:  2009-04       Impact factor: 4.075

Review 10.  The validity of biomarkers as surrogate endpoints in Alzheimer's disease by means of the Quantitative Surrogate Validation Level of Evidence Scheme (QSVLES).

Authors:  C C Gispen-de Wied; M Kritsidima; A J A Elferink
Journal:  J Nutr Health Aging       Date:  2009-04       Impact factor: 4.075

View more
  3 in total

1.  Editorial: can we improve care for patients with dementia?

Authors:  J E Morley
Journal:  J Nutr Health Aging       Date:  2011-08       Impact factor: 4.075

Review 2.  Cerebrospinal fluid and plasma biomarkers in Alzheimer disease.

Authors:  Kaj Blennow; Harald Hampel; Michael Weiner; Henrik Zetterberg
Journal:  Nat Rev Neurol       Date:  2010-02-16       Impact factor: 42.937

Review 3.  Fluid biomarkers in Alzheimer disease.

Authors:  Kaj Blennow; Henrik Zetterberg; Anne M Fagan
Journal:  Cold Spring Harb Perspect Med       Date:  2012-09-01       Impact factor: 6.915

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.